Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
Kissei Pharmaceutical Dividend Announcement
• Kissei Pharmaceutical announced a semi annually dividend of ¥45.00 per ordinary share which will be made payable on 2025-06-01. Ex dividend date: 2025-03-28
• Kissei Pharmaceutical's trailing twelve-month (TTM) dividend yield is 2.31%
Kissei Pharmaceutical Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2025-03-28 | ¥45.00 | semi annually | 2025-06-01 |
2024-09-27 | ¥45.00 | semi annually | 2024-12-03 |
2024-03-28 | ¥41.00 | semi annually | |
2023-09-28 | ¥41.00 | semi annually | 2023-12-04 |
2023-03-30 | ¥40.00 | semi annually | 2023-06-23 |
2022-09-29 | ¥40.00 | semi annually | 2022-12-02 |
2022-03-30 | ¥28.00 | semi annually | 2022-06-24 |
2021-09-29 | ¥28.00 | semi annually | 2021-12-02 |
2021-03-30 | ¥27.00 | semi annually | 2021-06-25 |
2020-09-29 | ¥27.00 | semi annually | 2020-12-03 |
2020-03-30 | ¥26.00 | semi annually | 2020-06-29 |
2019-09-27 | ¥26.00 | semi annually | 2019-12-05 |
2019-03-27 | ¥25.00 | semi annually | 2019-06-26 |
2018-09-26 | ¥25.00 | semi annually | 2018-12-06 |
2018-03-28 | ¥24.00 | semi annually | 2018-06-28 |
2017-09-27 | ¥24.00 | semi annually | 2017-12-06 |
2017-03-29 | ¥23.00 | semi annually | 2017-06-29 |
2016-09-28 | ¥23.00 | semi annually | |
2016-03-29 | ¥22.00 | semi annually | |
2015-09-28 | ¥22.00 | semi annually | |
2015-03-27 | ¥21.00 | semi annually | |
2014-09-26 | ¥21.00 | semi annually | |
2014-03-27 | ¥20.00 | semi annually |
Kissei Pharmaceutical Dividend per year
Kissei Pharmaceutical Dividend growth
Kissei Pharmaceutical Dividend Yield
Kissei Pharmaceutical current trailing twelve-month (TTM) dividend yield is 2.31%. Interested in purchasing Kissei Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:
Kissei Pharmaceutical Financial Ratios
Kissei Pharmaceutical Dividend FAQ
Other factors to consider when evaluating Kissei Pharmaceutical as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy Kissei Pharmaceutical stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: Kissei Pharmaceutical's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, Kissei Pharmaceutical publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, Kissei Pharmaceutical distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from Kissei Pharmaceutical are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: Kissei Pharmaceutical sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, Kissei Pharmaceutical distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: Kissei Pharmaceutical declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of Kissei Pharmaceutical's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review Kissei Pharmaceutical's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.